Format

Send to

Choose Destination
Clin Pharmacol Ther. 2012 Sep;92(3):283-6. doi: 10.1038/clpt.2012.122.

Model-based meta-analysis: an important tool for making quantitative decisions during drug development.

Author information

1
Projections Research, Inc., Phoenixville, Pennsylvania, USA. DRMould@PRI-Home.net

Abstract

Modeling during drug development is routinely used to integrate subject-level information, evaluate response, and inform clinical trials. Model-based meta-analysis (MBMA) combines aggregate safety and efficacy results from many trials. Because MBMA is based on results from large numbers of subjects, it increases the power to precisely detect small but clinically significant effects, providing a basis for quantitative drug development decisions and reducing time and cost. This Commentary describes an overview of MBMA and its application during drug development.

PMID:
22910485
DOI:
10.1038/clpt.2012.122
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center